Earum Pharmaceuticals Ltd (BSE: 542724) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹35 Cr, it ranks #4,141 by market cap among the 6,137 Indian listed companies on FinBizNet, and #53 of 63 in Pharmaceuticals. At ₹0.19 (as of 25 Oct 2026), the share price is 74.0% below its 52-week high of ₹0.73 and 0.0% above its 52-week low of ₹0.19. The share price is down 70.3% over one year and up 0.0% over three months.
| Current Price | ₹0.19 |
|---|---|
| Market Cap | ₹35 Cr |
| BSE Code | 542724 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 4.8 |
| Return on Equity | 5.69% |
| Return on Assets | 1.63% |
| 52-Week Range | ₹0.19 – ₹0.73 |
| 1-Year Price Change | -70.3% |
| 3-Month Price Change | 0.0% |
| Beta (1Y) | 0 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.earumpharma.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -104.3% |
| EPS (Basic) | ₹0.00 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Murae Organisor Limited engages in the trade in agriculture activities in India. The company was formerly known as Earum Pharmaceuticals Limited and changed its name to Murae Organisor Limited in November 2023. Murae Organisor Limited was incorporated in 2012 and is based in Ahmedabad, India.
1. Pharmaceuticals Intermediates-This segment engages in the manufacture, marketing, trading, and distribution of a range of pharmaceutical formulation products.
1. Trading in Agriculture Activities-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Earum Pharmaceuticals Ltd | ₹35 Cr | 4.8 | 5.69% | ₹0 Cr | -70.3% |
Listed by market capitalisation. Ratios are shown for context only.
Earum Pharmaceuticals Ltd is trading at ₹0.19, with a market capitalisation of ₹35 Cr.
Earum Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Earum Pharmaceuticals Ltd has a P/E of 4.8 and a return on equity of 5.69%.
Earum Pharmaceuticals Ltd is listed on the BSE under the scrip code 542724.
Earum Pharmaceuticals Ltd's share price is down 70.3% over one year and up 0.0% over three months. Its 52-week range is ₹0.19 to ₹0.73.
In Q1 FY26, Earum Pharmaceuticals Ltd reported revenue of ₹0 Cr and net profit of ₹-0 Cr, with basic EPS of ₹0 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.